{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T13:39:45Z","timestamp":1794663585258,"version":"4.9.1"},"reference-count":37,"publisher":"American Society of Hematology","issue":"14","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Although venetoclax-based lower-intensity regimens have greatly improved outcomes for older adults with acute myeloid leukemia (AML) who are unfit for intensive chemotherapy, the optimal induction for older patients with newly diagnosed AML who are suitable candidates for hematopoietic stem cell transplant (HSCT) is controversial. We retrospectively analyzed the post HSCT outcomes of 127 patients \u226560 years of age who received induction therapy at our institution with intensive chemotherapy (IC; n\u00a0= 44), lower-intensity therapy (LIT) without venetoclax (n\u00a0= 29), or LIT with venetoclax (n\u00a0= 54) and who underwent allogeneic HSCT in the first remission. The 2-year relapse-free survival (RFS) was 60% with LIT with venetoclax vs 54% with IC, and 41% with LIT without venetoclax; the 2-year overall survival (OS) was 72% LIT with venetoclax vs 58% with IC, and 41% with LIT without venetoclax. The benefit of LIT with venetoclax induction was greatest in patients with adverse-risk AML (2-year OS: 74%, 46%, and 29%, respectively). Induction with LIT, with or without venetoclax, was associated with the lowest rate of nonrelapse mortality (NRM) (2-year NRM: 17% vs 27% with IC; P\u00a0= .04). Using multivariate analysis, the type of induction therapy did not significantly affect any of the post HSCT outcomes evaluated; hematopoietic cell transplantation-specific comorbidity index was the only factor that independently predicted RFS and OS. LIT plus venetoclax followed by HSCT is a feasible treatment strategy in older, fit, HSCT-eligible patients with newly diagnosed AML and may be particularly beneficial for those with adverse-risk disease.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022009632","type":"journal-article","created":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T12:09:40Z","timestamp":1682597380000},"page":"3573-3581","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":28,"title":["Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2983-2738","authenticated-orcid":false,"given":"Nicholas J.","family":"Short","sequence":"first","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4442-2646","authenticated-orcid":false,"given":"Faustine","family":"Ong","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6350-2206","authenticated-orcid":false,"given":"Graciela","family":"Nogueras-Gonzalez","sequence":"additional","affiliation":[{"name":"2Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tapan M.","family":"Kadia","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7103-373X","authenticated-orcid":false,"given":"Naval","family":"Daver","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9003-0390","authenticated-orcid":false,"given":"Courtney D.","family":"DiNardo","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Konopleva","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Borthakur","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betul","family":"Oran","sequence":"additional","affiliation":[{"name":"3Department of Stem Cell Transplantation & Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gheath","family":"Al-Atrash","sequence":"additional","affiliation":[{"name":"3Department of Stem Cell Transplantation & Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8532-544X","authenticated-orcid":false,"given":"Rohtesh","family":"Mehta","sequence":"additional","affiliation":[{"name":"3Department of Stem Cell Transplantation & Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias J.","family":"Jabbour","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Musa","family":"Yilmaz","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4339-8683","authenticated-orcid":false,"given":"Ghayas C","family":"Issa","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Maiti","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4314-5037","authenticated-orcid":false,"given":"Richard E","family":"Champlin","sequence":"additional","affiliation":[{"name":"3Department of Stem Cell Transplantation & Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth J","family":"Shpall","sequence":"additional","affiliation":[{"name":"3Department of Stem Cell Transplantation & Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7592-2224","authenticated-orcid":false,"given":"Uday","family":"Popat","sequence":"additional","affiliation":[{"name":"3Department of Stem Cell Transplantation & Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,7,14]]},"reference":[{"key":"2023081117152089900_bib1","volume-title":"SEER Cancer Statistics Review, 1975-2017","year":"2020"},{"issue":"1","key":"2023081117152089900_bib2","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood-2011-04-347872","article-title":"Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007","volume":"119","author":"Dores","year":"2012","journal-title":"Blood"},{"issue":"18","key":"2023081117152089900_bib3","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1182\/blood-2008-07-172007","article-title":"Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry","volume":"113","author":"Juliusson","year":"2009","journal-title":"Blood"},{"issue":"12","key":"2023081117152089900_bib4","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1002\/cncr.33458","article-title":"De novo acute myeloid leukemia: a population-based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1980 to 2017","volume":"127","author":"Sasaki","year":"2021","journal-title":"Cancer"},{"issue":"10147","key":"2023081117152089900_bib5","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0140-6736(18)31041-9","article-title":"Acute myeloid leukaemia","volume":"392","author":"Short","year":"2018","journal-title":"Lancet"},{"issue":"7","key":"2023081117152089900_bib6","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2023081117152089900_bib7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"issue":"24","key":"2023081117152089900_bib8","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"issue":"7","key":"2023081117152089900_bib9","doi-asserted-by":"crossref","first-page":"e535","DOI":"10.1016\/S2352-3026(22)00167-3","article-title":"Choosing between intensive and less intensive front-line treatment approaches for older patients with newly diagnosed acute myeloid leukaemia","volume":"9","author":"Short","year":"2022","journal-title":"Lancet Haematol"},{"issue":"5","key":"2023081117152089900_bib10","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/cncr.21723","article-title":"Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"issue":"2","key":"2023081117152089900_bib11","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00277-021-04693-8","article-title":"Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission after 5-azacitidine and venetoclax: a multicenter retrospective study","volume":"101","author":"Pasvolsky","year":"2022","journal-title":"Ann Hematol"},{"issue":"6","key":"2023081117152089900_bib12","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1111\/bjh.17996","article-title":"Venetoclax and hypomethylating agents yield high response rates and favourable transplant outcomes in patients with newly diagnosed acute myeloid leukaemia","volume":"196","author":"Salhotra","year":"2022","journal-title":"Br J Haematol"},{"issue":"10","key":"2023081117152089900_bib13","doi-asserted-by":"crossref","first-page":"694.e1","DOI":"10.1016\/j.jtct.2022.07.022","article-title":"Outcomes are similar after allogeneic hematopoietic stem cell transplant for newly diagnosed acute myeloid leukemia patients who received venetoclax\u00a0+ azacitidine versus intensive chemotherapy","volume":"28","author":"Winters","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"2023081117152089900_bib14","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/ajh.26190","article-title":"Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice","volume":"96","author":"Apel","year":"2021","journal-title":"Am J Hematol"},{"issue":"12","key":"2023081117152089900_bib15","doi-asserted-by":"crossref","first-page":"e322","DOI":"10.1016\/j.bbmt.2020.08.027","article-title":"Outcome of allogeneic hematopoietic cell transplantation after venetoclax and hypomethylating agent therapy for acute myelogenous leukemia","volume":"26","author":"Sandhu","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2023081117152089900_bib16","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41409-021-01476-7","article-title":"Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60","volume":"57","author":"Pollyea","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"2023081117152089900_bib17","doi-asserted-by":"crossref","first-page":"e724","DOI":"10.1016\/S2352-3026(20)30210-6","article-title":"10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial","volume":"7","author":"DiNardo","year":"2020","journal-title":"Lancet Haematol"},{"issue":"1","key":"2023081117152089900_bib18","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13045-022-01229-z","article-title":"Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure","volume":"15","author":"Short","year":"2022","journal-title":"J\u00a0Hematol Oncol"},{"issue":"4","key":"2023081117152089900_bib19","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Dohner","year":"2017","journal-title":"Blood"},{"issue":"3","key":"2023081117152089900_bib20","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/cncr.30361","article-title":"Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia","volume":"123","author":"Ravandi","year":"2017","journal-title":"Cancer"},{"issue":"26","key":"2023081117152089900_bib21","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"issue":"12","key":"2023081117152089900_bib22","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. diagnosis and staging working group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2023081117152089900_bib23","first-page":"825","article-title":"1994 consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"2023081117152089900_bib24","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A\u00a0note on quantifying follow-up in studies of failure time","volume":"17","author":"Schemper","year":"1996","journal-title":"Contr Clin Trials"},{"issue":"6","key":"2023081117152089900_bib25","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","article-title":"Estimation of failure probabilities in the presence of competing risks: new representations of old estimators","volume":"18","author":"Gooley","year":"1999","journal-title":"Stat Med"},{"issue":"446","key":"2023081117152089900_bib26","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A\u00a0proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J\u00a0Am Stat Assoc"},{"issue":"4","key":"2023081117152089900_bib28","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.bbmt.2006.11.024","article-title":"Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan","volume":"13","author":"Oran","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"2023081117152089900_bib27","doi-asserted-by":"crossref","first-page":"e532","DOI":"10.1016\/S2352-3026(18)30156-X","article-title":"Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial","volume":"5","author":"Popat","year":"2018","journal-title":"Lancet Haematol"},{"issue":"28","key":"2023081117152089900_bib29","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1200\/JCO.21.00960","article-title":"When less is more: reevaluating the role of intensive chemotherapy for older adults with acute myeloid leukemia in the modern era","volume":"39","author":"Short","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2023081117152089900_bib30","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/ajh.26061","article-title":"Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality","volume":"96","author":"Maiti","year":"2021","journal-title":"Am J Hematol"},{"issue":"5","key":"2023081117152089900_bib31","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3324\/haematol.2016.159343","article-title":"Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis","volume":"102","author":"Buckley","year":"2017","journal-title":"Haematologica"},{"issue":"3","key":"2023081117152089900_bib32","doi-asserted-by":"crossref","first-page":"256.e1","DOI":"10.1016\/j.jtct.2020.12.021","article-title":"ELN 2017 genetic risk stratification predicts survival of acute myeloid leukemia patients receiving allogeneic hematopoietic stem cell transplantation","volume":"27","author":"Hansen","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"5","key":"2023081117152089900_bib33","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41409-017-0021-4","article-title":"Geriatric assessment and quality of life in older patients considered for allogeneic hematopoietic cell transplantation: a prospective risk factor and serial assessment analysis","volume":"53","author":"Deschler","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"2023081117152089900_bib34","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.3324\/haematol.2014.103655","article-title":"Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients","volume":"99","author":"Muffly","year":"2014","journal-title":"Haematologica"},{"issue":"12","key":"2023081117152089900_bib35","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1182\/bloodadvances.2020001719","article-title":"Geriatric assessment in older alloHCT recipients: association of functional and cognitive impairment with outcomes","volume":"4","author":"Olin","year":"2020","journal-title":"Blood Adv"},{"issue":"8","key":"2023081117152089900_bib36","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"2023081117152089900_bib37","unstructured":"Network NCC. Accessed 23 November 2022. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/aml.pdf."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/14\/3573\/2070642\/blooda_adv-2022-009632-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/14\/3573\/2070642\/blooda_adv-2022-009632-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T13:15:47Z","timestamp":1691759747000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/14\/3573\/495511\/Impact-of-type-of-induction-therapy-on-outcomes-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,14]]},"references-count":37,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2023,7,25]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022009632","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,14]]}}}